Actinium Pharmaceuticals, Inc. (ATNM) Net income 2016–2025
Actinium Pharmaceuticals, Inc. (ATNM) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$33.9MFY2025 · since FY2016: -$24.3M → -$33.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$33.9M | +11.4% |
| FY2024 | -$38.2M | +21.7% |
| FY2023 | -$48.8M | -47.9% |
| FY2022 | -$33.0M | -33.3% |
| FY2021 | -$24.8M | -11.5% |
| FY2020 | -$22.2M | -1.4% |
| FY2019 | -$21.9M | +7.4% |
| FY2018 | -$23.7M | +11.1% |
| FY2017 | -$26.6M | -9.4% |
| FY2016 | -$24.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ATNM financial trends
ATNM RevenueATNM Net marginATNM Gross profitATNM Gross marginATNM Operating incomeATNM Operating marginATNM Operating cash flowATNM Free cash flowATNM Capital expendituresATNM Return on equityATNM Stock buybacksATNM Dividends paidATNM Total assetsATNM Total liabilitiesATNM Shareholders’ equityATNM overview →